FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like FDA Focus Area Report for 2022 Expands on Oncology, Rare Disease Research September 9, 2022 California OTC Drugmaker Flagged for Numerous Violations July 6, 2018 FDA to Give Companies Advance Notice of Generic RTRs, CRLs and Approvals October 6, 2017